Mkts

INmune Bio Inc.

NASDAQ: INMB
$0.89-0.14 (-13.19%)
As of Nov 19, 4:00 PM ET

Key statistics

Day range
0.891.03
52-week range
0.892.60
Today
Open1.03
Previous close0.89
Volume—
Valuation
Market cap31.89M
P/E ratio—
EPS (TTM)-0.69
Income & risk
Dividend / yield—
Beta1.10
Avg volume357.1K
Discussion

INMB News

Stories mentioning INMB from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue50.00
Cost of Goods Sold
Gross Profit0.000.000.000.000.00
Operating Expenses
Research & Development3,6412,3294,8875,8047,6397,35310,0677,053
Sales General & Admin
Total Operating Expenses5,8125,4747,43324,5719,9559,46712,2869,865
Operating Income (Loss)(5,812)(5,474)(7,433)(24,571)(9,905)(9,467)(12,286)(9,865)
Interest Income
Interest Expense0.0037.00145.00250.00
Other Expense166.00
Pretax Income
Tax Provision
Net Income (Loss)(5,407)(5,264)(6,472)(24,458)(9,739)(9,218)(12,093)(9,746)
Earnings Per Share (Basic)(0.20)(0.21)(0.24)(1.05)(0.43)(0.46)(0.60)(0.50)
Earnings Per Share (Diluted)(0.20)(0.21)(0.24)(1.05)(0.43)(0.46)(0.60)(0.50)
Weighted Average Shares Outstanding (Basic)26,58524,75826,58523,29822,49619,94420,18619,307
Weighted Average Shares Outstanding (Diluted)26,58524,75826,58523,29822,49619,94420,18619,307

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About INMB

INmune Bio Inc. (NASDAQ: INMB) is a stock listed on the Nasdaq Stock Market under the ticker symbol INMB. It last traded at $0.8900 (Nov 19, 2026, 4:00 PM ET), down 13.2% on the day. That gives INmune Bio a market capitalisation of $31.9M.

Over the past 52 weeks INMB has traded between $0.8900 and $2.60.

For the quarter ended Mar 31, 2026 it reported a net loss of $5.4M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$5.4M
Dec 31, 2025—-$5.3M
Sep 30, 2025—-$6.5M
Jun 30, 2025—-$24.5M

From INmune Bio’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…